Alzamend Neuro is trading 7.24% up now at $1.63 in pre-market after positive late-stage personalized cancer-vaccine results from Moderna and Merck lifted biotechnology sentiment.
- XBI was up 2.27% pre-market, supporting an industry-wide catalyst rather than new company-specific news.
- Recent company announcements included lithium-imaging data accepted for an oral presentation; no fresh August 20 catalyst was identified.